Photocure ASA · OSL:PHO
Photocure ASA — Q1 2007 Earnings Presentation
21 slides from Photocure ASA's earnings presentation, Apr 25, 2007
Slide 1: First quarter 2007
Brilliance in photodynamic technology TM First quarter 2007 April 25th, 2007 Kjetil Hestdal, President & CEO and Christian Fekete, CFO
Slide 2: Hexvix commercialisation gaining momentum
Hexvix commercialisation gaining momentum Hexvix revenue increased to MNOK 2.1 (0.1) in rest of Europe Hexvix revenue increased to MNOK 1.6 (0.3) in the Nordic region Increased sales of Metvix Metvix revenue increased 33% outside the Nordic region to MNOK 9.9 Metvix revenue MNOK 5.4 (5.4) in the Nor
Slide 3: Brilliance in photodynamic technology
Brilliance in photodynamic technology TM
Slide 4: Financial statements - Profit & loss first quarter 2007 (group)
Financial statements - Profit & loss first quarter 2007 (group) Sales revenues increasing by 43% to MNOK 19.0 New classification of expenses from 1.1.2007 2007 2006 2006 1.1-31.03 1.1-31.03 1.1-31.12 Sales revenues 19 006 13 285 61 667 Signing fee and m ilestone revenues 3 908 60 538 148 653 Total r
Slide 5: Financial statements - Segment information (group)
Financial statements - Segment information (group) Sales revenues for Metvix ROW increasing by 33% to MNOK 9.9 Sales revenues for Hexvix increasing to MNOK 3.7 R&D separate segment from 1.1.2007 Income statement - geographical distribution (Amounts in NOK 1000) 1Q07 1Q06 Nordic ROW R&D* Total Nordic
Slide 6: Financial statements - balance sheet 31.03.2007 (group)
Financial statements - balance sheet 31.03.2007 (group) Cash & cash quivalents of MNOK 316.8 per 31.3.2007 Total balance of MNOK 354.5 per 31.3.2007 31.03.2007 31.03.2006 31.12.2006 N on-currrent assets Intangible assets, software 766 0 780 M achinery & equipm ent 2 166 2 844 2 178 T otal non-curren
Slide 7: Hexvix - a breakthrough in bladder cancer diagnostics
Brilliance in photodynamic technology TM ® - a breakthrough in bladder cancer diagnostics
Slide 8: Excellent feedback from urologists at EAU, Berlin satellite symposium
Excellent feedback from urologists at EAU, Berlin satellite symposium European awareness increasing Critical success factors: Establish reimbursement - ongoing Increase base of scopes ongoing Train urologists - ongoing Introduced in Germany, Austria, France, Spain, Portugal, UK, Baltics and Greece.
Slide 9: Audience Key messages
Audience Key messages Urologists detects 30% more patients with bladder cancer detects 67% more CIS lesions improves management in 1 in 5 patients Payors is cost-effective is the only licensed product of its type is proven to be effective with a well-controlled clinical programme Patients and improv
Slide 10: Metvix - treatment of skin cancer without scarring
Brilliance in photodynamic technology TM ® ® - treatment of skin cancer without scarring
Slide 11: Approved for AK, BCC and Bowen's disease in EU
Approved for AK, BCC and Bowen s disease in EU 15 million patients diagnosed with AK annually in EU/US Topical treatments gaining market share Metvix offers patient benefits superior cosmetic outcome Reimbursement is critical for Metvix growth
Slide 12: Metvix recommended as first-line treatment in IPDT guidelines
Metvix recommended as first-line treatment in IPDT guidelines PDT is recommended as first-line treatment for AK, BD and sBCC in new International peer reviewed guidelines. Treatment of NMSC (other than SCC) should be driven by: efficacy, with due consideration to cosmetic outcome, and patient prefer
Slide 13: R&D - acne, cervix, colon and PCI Biotech
Brilliance in photodynamic technology TM - acne, cervix, colon and PCI Biotech
Slide 14: Acne market and US doctor visits
Each year US doctors register ~ 3 million visits concerning acne, app. 70% of these have moderate to severe acne Market for treatment of moderate to severe acne USD 1.3 billion per year Existing treatments have significant side effects Photocure has a patented technology in Acne patient before treat
Slide 15: Started development of new lamp; started phase IIb study
Started development of new lamp Started phase IIb study Moderate to severe acne Over 200 patients in the US Dose finding Placebo controlled Primary endpoint: reduction of lesion counts Report scheduled for H108 Filed new method of use patents in acne and other dermatology indications Illustration of
Slide 16: Cervix first phase I/II study on schedule
Cervix first phase I/II study on schedule Medical need for effective treatment of HPV infection and premalignant lesions Large patient population over 3.5 million in US Phase I/II study ongoing: dose finding Norway and Germany approx. 80 patients 6 month follow-up report scheduled for H2 2008 Starte
Slide 17: High medical need for early detection of colon cancer
High medical need for early detection of colon cancer. Inadequate methods available today: 22% miss rate on polyps 62% miss rate on flat lesions Huge endoscopy variation 13 million colonoscopies performed annually in EU/US Phase I/II study ongoing: dose-finding 2 centres in Germany approx. 30 patien
Slide 18: Colon cancer study design and results
Investigator: Dr. Mayinger, Münich Study design: 12 patients with suspected colon cancer 30-60 min HAL enema white + blue light inspection Results: 64 polyps Detection rate HAL+blue light 98% Detection rate white light 72% No side effects 18 Courtesy Mayinger, Munich
Slide 19: The PCI technology can significantly enhance delivery of siRNA
The PCI technology can significantly enhance delivery of siRNA Two patent applications filed on a combination of PCI technology and oligonucleotide molecules (siRNA and PNA) therapy. The goal is to deliver tailored cancer therapy. New research agreement with Radium Hospital on development of PCI wit
Slide 20: Continue investing in Metvix and Aktilite
Continue investing in Metvix and Aktilite Support Galderma in strengthening Metvix/Aktilite in dermatology Seek Aktilite approval in the US Commercialise Hexvix Support GE Healthcare in introducing Hexvix in EU Seek Hexvix approval in the US Continue clinical development in acne, cervix, colon and P
Slide 21: This document was created with Win2PDF available at http://www.win2pdf.com. The unregistered version of Win2PDF
This document was created with Win2PDF available at http://www.win2pdf.com. The unregistered version of Win2PDF is for evaluation or non-commercial use only.